Would you treat a patient with refractory, metastatic castrate resistant prostate cancer who has somatic ATM mutation with a PARP inhibitor?
Does the specimen (blood vs tissue) used to detect mutation affect your consideration?
Answer from: Medical Oncologist at Community Practice
Yes, I would consider Olaparib (not Rucaparib), but only after they have received at least two AR-targeting drugs and at least one taxane drug, and only if an ATR inhibitor trial was not available. And I would set the expectations really low: PSA response rate of 5-10%, PFS of 4-6 months.
Sign in or Register to read more